

Dear Colleague

SERIOUS SHORTAGE PROTOCOL: ESTRADIOL (LENZETTO®) 1.53MG/DOSE TRANSDERMAL SPRAY - SUBSTITUTION

Purpose

1. To advise of a Serious Shortage Protocol (SSP) in place for estradiol (Lenzetto®) 1.53mg/dose transdermal spray, from 19 May to 19 August 2022.

Background

2. Changes made to the Human Medicines Regulations 2012 and the NHS (Pharmaceutical Services) (Scotland) Regulations 2009, the latter of which became effective from 31 October 2019, allow the use of Serious Shortage Protocols (SSPs).
3. An SSP is an additional tool to manage and mitigate medication shortages and may be used when other measures have been exhausted or are likely to be ineffective. There are two types of SSP; one that covers prescription only medicines and another that covers pharmacy and general sales list medicines and appliances.
4. Each SSP is individually developed and authorised clinically, to enable community pharmacists and dispensing doctors to dispense a different strength or formulation or alternative medicine or appliances in accordance with the protocol, rather than having to refer prescribing decisions back to the original prescriber. These protocols are time limited.
5. Community pharmacists are expected to use their professional skill and judgement to decide whether it is reasonable and appropriate to substitute a person's prescribed medicine using the SSP. The person will also have to agree to the alternative supply.

23 May 2022

Addresses

For action

Chief Executives, NHS Boards
Director Practitioner Services,
NHS NSS

For information

Directors of Pharmacy
NHS Medical Directors

Enquiries to:

Pharmacy Team
1st Floor East Rear
St Andrew's House
EDINBURGH
EH1 3DG

Email:

PharmacyTeam@gov.scot

www.gov.scot

6. Certain classes of medicines, for example cytotoxic medicines, biologics, anti-epileptic medicines and certain antipsychotic medicines, are not considered to be suitable for SSPs due to concerns about ensuring bioequivalence. In these cases, people should be referred back to the prescriber for any decision about their treatment before any therapeutic or generic alternative is supplied.

Medicine supply situation requiring the use of an SSP

7. A supply issue with estradiol (Lenzetto®) 1.53mg/dose transdermal spray has been identified. In order to manage stock supplies fairly and effectively, there are three UK-wide SSPs in place for this particular product:
 - [SSP 026](#) – Where the duration of treatment on the prescription is for more than three months of estradiol (Lenzetto®) 1.53mg/dose transdermal spray and supplies of estradiol (Lenzetto®) 1.53mg/dose transdermal spray are available.
 - **[SSP 027](#) – Where the duration of treatment on the prescription is for three months or less of estradiol (Lenzetto®) 1.53mg/dose transdermal spray, supplies of estradiol (Lenzetto®) 1.53mg/dose transdermal spray are unavailable, and substitution is deemed clinically appropriate.**
 - [SSP 028](#) – Where the duration of treatment on the prescription is for more than three months of estradiol (Lenzetto®) 1.53mg/dose transdermal spray, supplies of estradiol (Lenzetto®) 1.53mg/dose transdermal spray are unavailable, and substitution is deemed clinically appropriate.
8. **This circular refers to [SSP 027](#)**, where the duration of treatment on the prescription is for three months or less of estradiol (Lenzetto®) 1.53mg/dose transdermal spray, supplies of this product are unavailable, and substitution is deemed clinically appropriate. A substituted product can be given for the prescribed duration of treatment.

Operational overview

9. Between 19 May and 19 August 2022, for patients presenting with an NHS or private prescription for a supply of three months or less of estradiol (Lenzetto®) 1.53mg/dose transdermal spray, community pharmacists may substitute this product with an equivalent dose of estradiol patches in accordance with the SSP for eligible patients (see additional information below). Guidance on dose conversion of estradiol (Lenzetto®) 1.53mg/dose transdermal spray to estradiol patches is provided within [SSP 027](#).
10. When a substitution is made, pharmacists need to ensure that the patient's prescriber and/or GP practice is notified in accordance with this SSP within 24 hours.
11. Particular care and caution should be taken to provide advice to patients who are considered at higher risk of experiencing the **nocebo** effect. Patients should be reassured as to the appropriateness and effectiveness of this alternative treatment as per the counselling points noted under this SSP. If there are significant concerns, patient needs to be referred back to their prescriber for further advice.

12. If a patient or their carer declines to receive the medicine under this SSP, the pharmacist should use their professional judgement to determine if other courses of action are appropriate whilst taking into consideration wider supply issues. If this does not address their concerns, the patient should be referred back to their prescriber for advice.

Additional information

13. Please see links for further advice on alternative hormone replacement therapies:

- [CKS Hormone replacement therapy](#)
- [British Menopause Society – HRT preparations and equivalent alternatives](#)

14. Please see the link for advice on the [availability of alternatives](#).

Fees and Endorsements

15. When an SSP is introduced, the pharmacist should use the Other endorsement function quoting SSP and the relevant reference number – in this case add SSP 027. A community pharmacy contractor will receive a multiplier per item of 5 (x5), via the dispensing pool, for any necessary supply in accordance with SSPs. Endorsements must be made in line with the SSP to be eligible for payment.

16. The paper form should be endorsed PMR with details added of what was supplied as well as 'SSP 027' annotated. This is to ensure accurate reimbursement for non-barcoded forms or where an electronic claim message is unavailable.

Enquiries

17. For any queries on the detail of this SSP, please contact the Scottish Government Pharmacy Team at PharmacyTeam@gov.scot.

Action

18. Health Boards are asked to note the contents of this Circular and to bring it to the attention of community pharmacy contractors on their Pharmaceutical Lists and Area Pharmaceutical Committees. This Circular should also be brought to the attention of General Practices.

Yours sincerely



Alison Strath
Chief Pharmaceutical Officer